These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35571584)

  • 1. Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory.
    Yoon JP; Jung YS; Kim DH
    JSES Rev Rep Tech; 2022 Aug; 2(3):376-379. PubMed ID: 35571584
    [No Abstract]   [Full Text] [Related]  

  • 2. Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female.
    Majid I; Mearaj S
    Dermatol Ther; 2021 Nov; 34(6):e15146. PubMed ID: 34590397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
    Sønderskov KM; Dinesen PT; Østergaard SD
    Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    MacIntyre CR; Veness B; Berger D; Hamad N; Bari N
    Vaccine; 2021 Aug; 39(34):4784-4787. PubMed ID: 34272095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure.
    Wolf ME; Luz B; Niehaus L; Bhogal P; Bäzner H; Henkes H
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33918932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review.
    da Gama PD; de Alcantara TG; Smaniotto RR; Petuco PL; de Almeida WA; da Gama RAD; Fragoso YD
    Case Rep Neurol Med; 2022; 2022():8999853. PubMed ID: 35692661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study.
    Yesuf EA; Riad A; Sofi-Mahmudi A; Sudhakar M; Mekonnen A; Endalkachew S; Mama F; Muhidin S; Ayele B; Yahya M; Usman A; Abafita J; Klugar M
    Front Public Health; 2022; 10():937794. PubMed ID: 35928493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Nantanee R; Aikphaibul P; Jaru-Ampornpan P; Sodsai P; Himananto O; Theerawit T; Sophonphan J; Tovichayathamrong P; Manothummetha K; Laohasereekul T; Hiransuthikul N; Hirankarn N; Puthanakit T;
    Vaccine; 2022 May; 40(24):3320-3329. PubMed ID: 35513961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Eosinophilic Pneumonia Associated With the Anti-COVID-19 Vaccine AZD1222.
    Miqdadi A; Herrag M
    Cureus; 2021 Oct; 13(10):e18959. PubMed ID: 34812326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Immediate Allergic Reactions After Immunization With the Pfizer BNT162b2 Vaccine Using Intradermal Skin Testing With the COVID-19 Vaccines.
    Shavit R; Maoz-Segal R; Offengenden I; Yahia SH; Maayan DM; Lifshitz Y; Niznik S; Deutch M; Elbaz E; Genaim H; Iancovici-Kidon M; Agmon-Levin N
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2677-2684. PubMed ID: 35973526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.
    Fragoso YD; Gomes S; Gonçalves MVM; Mendes Junior E; Oliveira BES; Rocha CF; Santos GACD; Tauil CB; Araujo RV; Peron JPS
    Mult Scler Relat Disord; 2022 Jan; 57():103321. PubMed ID: 35158439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
    Hwang YH; Song KH; Choi Y; Go S; Choi SJ; Jung J; Kang CK; Choe PG; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2021 Nov; 36(6):1486-1491. PubMed ID: 34038996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
    Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
    Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of delayed second dose of AZD1222 vaccine in patients with autoimmune rheumatic disease.
    Mehta P; Paul A; Ahmed S; Cherian S; Panthak A; Benny J; Shenoy P
    Clin Rheumatol; 2022 Nov; 41(11):3537-3542. PubMed ID: 35760938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine.
    Alhammad NS; Milibary HH; Baghdadi RR; Alawadi TM; Hudairy RE
    Cureus; 2022 May; 14(5):e24649. PubMed ID: 35663693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.
    Leclerc S; Royal V; Lamarche C; Laurin LP
    Am J Kidney Dis; 2021 Oct; 78(4):607-610. PubMed ID: 34242687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.